Novel Therapeutic Approach to Hypercholesterolemia Using Anti-PCSK9 Selected Immune Repertoires

Period of Performance: 09/01/2017 - 08/31/2018


Phase 2 SBIR

Recipient Firm

Abeome Corporation
ATHENS, GA 30602
Principal Investigator


? DESCRIPTION (provided by applicant): We have developed and completed a proof-of-principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to PCSK9 injection, and have identified a set of high affinity neutralizing antibodies which will be tested in animals for efficacy and potency.